![](/wp-content/uploads/2020/10/AmgenServierCytokineticsTrials.png)
$599
GALACTIC-HF Results Disappoint; Omecamtiv Approval, but Utility is Questionable
Amgen, Cytokinetics, and Servier announced topline results from the Ph3 GALACTIC–HF trial, evaluating omecamtiv mecarbil in patients with HFrEF. Results demonstrated a statistically significant 8% RRR in the primary composite endpoint (CV death or HF events) but failed to show a benefit in CV death alone. Below, FENIX provides an overview of the topline data and thoughts on the results.